UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Journal of clinical oncology, 2017-11, Vol.35 (32), p.3638-3646

2017

Volltextzugriff (PDF)

Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models

JNCI : Journal of the National Cancer Institute, 2010-05, Vol.102 (10), p.680-691

2010

Volltextzugriff (PDF)

Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer

Journal of clinical oncology, 2012-02, Vol.30 (6), p.587-592

2012

Volltextzugriff (PDF)

Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies

Cancer treatment reviews, 2012-10, Vol.38 (6), p.708-714

2012

Volltextzugriff (PDF)

Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing

Modern pathology, 2019-12, Vol.32 (12), p.1823-1833

2019

Volltextzugriff (PDF)

Evaluation of a comprehensive geriatric assessment tool in geriatric cancer patients undergoing adjuvant chemotherapy: a pilot study

Supportive care in cancer, 2019-05, Vol.27 (5), p.1871-1877

2019

Volltextzugriff (PDF)

Overcoming endocrine resistance in breast cancer—are signal transduction inhibitors the answer?

Breast cancer research and treatment, 2008-04, Vol.108 (3), p.307-317

2008

Volltextzugriff (PDF)

A phase 2 trial exploring the effects of high‐dose (10,000 IU/day) vitamin D3 in breast cancer patients with bone metastases

Cancer, 2010-01, Vol.116 (2), p.284-291

2010

Volltextzugriff (PDF)

The role of palliative care in the lung cancer patient: can we improve quality while limiting futile care?

Current opinion in pulmonary medicine, 2009-07, Vol.15 (4), p.321-326

2009

Volltextzugriff (PDF)

Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?

Critical reviews in oncology/hematology, 2009-10, Vol.72 (1), p.56-64

2009

Volltextzugriff (PDF)

Approach to inflammatory breast cancer

Canadian family physician, 2009-01, Vol.55 (1), p.25-31

2009

Volltextzugriff (PDF)

Delayed hypersensitivity reactions to multiple aromatase inhibitors followed by successful desensitization to letrozole

Annals of allergy, asthma, & immunology, 2021-09, Vol.127 (3), p.378-379

2021

Volltextzugriff (PDF)

Abstract OT1-07-01: MRI screening versus symptom-directed surveillance for brain metastases among patients with triple negative or HER2+ metastatic breast cancer: A pilot study (nct03881605)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT1-07-01-OT1-07-01

2022

Volltextzugriff (PDF)

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

Journal of clinical oncology, 2023-01, Vol.41 (2), p.198-205

2023

Volltextzugriff (PDF)

Abstract OT1-01-01: A randomized, pragmatic trial investigating the timing of radiotherapy and endocrine in patients with early stage breast cancer (REaCT-RETT trial)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT1-01-01-OT1-01-01

2022

Volltextzugriff (PDF)

Underestimation of risk by Gail model extends beyond women with atypical hyperplasia

Journal of clinical oncology, 2009-03, Vol.27 (9), p.1526; author reply 1527-1526

2009

Volltextzugriff (PDF)

Chemotherapy Dose-dense treatment for triple-negative breast cancer

Nature reviews. Clinical oncology, 2010-02, Vol.7 (2), p.79-80

2010

Volltextzugriff (PDF)

Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD8-01-PD8-01

2022

Volltextzugriff (PDF)

A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer

Current oncology (Toronto), 2024-08, Vol.31 (8), p.4531-4545

2024

Volltextzugriff (PDF)

Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients

Supportive care in cancer, 2017-06, Vol.25 (6), p.1881-1886

2017

Volltextzugriff (PDF)

A phase 2 trial exploring the effects of high‐dose (10,000 IU/day) vitamin D 3 in breast cancer patients with bone metastases

Cancer, 2010-01, Vol.116 (2), p.284-291

2010

Volltextzugriff (PDF)

Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors

Cancer and metastasis reviews, 2014-03, Vol.33 (1), p.295-307

2014

Volltextzugriff (PDF)

Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer

Cancer treatment reviews, 2010-08, Vol.36 (5), p.410-415

2010

Volltextzugriff (PDF)

Randomized Feasibility Study of De-escalated (Every 12 wk) Versus Standard (Every 3 to 4 wk) Intravenous Pamidronate in Women With Low-risk Bone Metastases From Breast Cancer

American journal of clinical oncology, 2013-10, Vol.36 (5), p.436-442

2013

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(42)

Publikationsform

Sprache

Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(30)
Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Female
(25)
Oncology
(20)
Breast Cancer
(16)
Breast Neoplasms - Drug Therapy
(16)
Aged
(10)
Adult
(9)
Middle Aged
(9)
Biological And Medical Sciences
(8)
Medical Sciences
(8)
Tumors
(8)
Chemotherapy
(7)
Aged, 80 And Over
(6)
Breast Neoplasms - Pathology
(6)
Cancer
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Care And Treatment
(5)
Gynecology. Andrology. Obstetrics
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models

Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer

Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies

Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing

Evaluation of a comprehensive geriatric assessment tool in geriatric cancer patients undergoing adjuvant chemotherapy: a pilot study

Overcoming endocrine resistance in breast cancer—are signal transduction inhibitors the answer?

A phase 2 trial exploring the effects of high‐dose (10,000 IU/day) vitamin D3 in breast cancer patients with bone metastases

The role of palliative care in the lung cancer patient: can we improve quality while limiting futile care?

Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?

Approach to inflammatory breast cancer

Delayed hypersensitivity reactions to multiple aromatase inhibitors followed by successful desensitization to letrozole

Abstract OT1-07-01: MRI screening versus symptom-directed surveillance for brain metastases among patients with triple negative or HER2+ metastatic breast cancer: A pilot study (nct03881605)

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

Abstract OT1-01-01: A randomized, pragmatic trial investigating the timing of radiotherapy and endocrine in patients with early stage breast cancer (REaCT-RETT trial)

Underestimation of risk by Gail model extends beyond women with atypical hyperplasia

Chemotherapy Dose-dense treatment for triple-negative breast cancer

Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis

A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer

Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients

A phase 2 trial exploring the effects of high‐dose (10,000 IU/day) vitamin D 3 in breast cancer patients with bone metastases

Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors

Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer

Randomized Feasibility Study of De-escalated (Every 12 wk) Versus Standard (Every 3 to 4 wk) Intravenous Pamidronate in Women With Low-risk Bone Metastases From Breast Cancer

Aktive Filter

Suchergebnisse filtern